Earnix Welcomes New CEO to Lead Next Stage of Global Expansion
Earnix, the market-leading provider of mission-critical cloud-based intelligent real-time, dynamic pricing and rating solutions for insurers and banks, today announced it is appointing insurance and fintech industry veteran, Robin Gilthorpe, as its new Chief Executive Officer effective February 1, 2023. Mr. Gilthorpe will be taking over the helm from Mr. Udi Ziv, who served as the company’s CEO over the past six years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005784/en/
Robin Gilthorpe, CEO, Earnix (Photo: Business Wire)
Robin Gilthorpe, a veteran of the finance and insurance industries, brings to the role over 25 years of experience as a successful business leader. Throughout his career, Mr. Gilthorpe has held numerous executive leadership roles at leading technology and insurance companies such as TIBCO, Vertexone, Watersmart Software, DataSynapse and ESW Capital. In his most recent role at Insurtech innovator Salty, Gilthorpe served as Chief Operating Officer, generating a nine-figure outcome in sale to CDK Global.
“I am thrilled to be joining Earnix at this crucial time in the global economy,”said Robin Gilthrope, incoming CEO at Earnix. “Financial services companies across the globe are seeking intelligent operations to ensure they can offer real-time, dynamic solutions, to better serve customers, enabling them to be more agile, nimble, attentive, and responsive. Today’s end-customer demands unparalleled experience, alongside highly personalized and customizable solutions. Earnix solutions serve as the go-to platform for financial services companies to address the growing demands of the world’s leading financial and insurance companies.”
His hiring comes on the heels of a period of growth for Earnix led by exiting CEO Udi Ziv. Mr. Ziv joined Earnix in 2017 and in his six years with the firm has led the company to consistent growth, achieving Unicorn status and important strategic alliances including forging the recently announced strategic partnership with Guidewire as well as engagements with USAA, MAPFRE, IAG, Liberty Mutual, US Bank, Lloyd’s Banking Group, and many more. Mr. Ziv built a strong team of leaders positioned to drive the company’s continued growth. Udi will serve as one of the industry experts on the Earnix Board of directors.
“We are proud to welcome Robin to the Earnix family, and believe that his experience in building global, international companies, alongside the growing demand for Earnix’s suite of real-time, dynamic, composable Intelligent InsurOps solutions, will lead Earnix to significant growth over the next few years, and bring Earnix to international market leadership, with its real-time operation platform for the largest insurance companies and banking institutions,” said Erel Margalit, JVP Founder & Executive Chairman and Earnix's Chairman of the Board, “We want to thank Udi for his important role, over the last few years. With its growing presence in North America, Europe, Asia Pacific, and Israel, Earnix will continue to strive to become the category leader, in the real-time AI usage-based insurance and banking industry.”
“I’ve very much enjoyed my tenure at Earnix, leading the company to consistent year over year growth, and strongly believe in our people and products as a change agent for financial services companies,” Udi Ziv, exiting CEO, Earnix, said. “I believe now is the time to move on to my next endeavor as the company prepares for its next stage of international expansion. I firmly believe I am leaving the company in very capable hands with Robin and expect that the company will continue the rapid global growth Earnix has experienced in the last few years.”
About Earnix
Earnix is the premier provider of mission-critical composable and cloud-based intelligent solutions across pricing, rating, underwriting, product personalization and telematics. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. It has been innovating for Insurers and Banks since 2001 with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix shareholders include JVP, Insight Partners, IGP, and Vintage Investment Partners.
For more information please visit: earnix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005784/en/
Contact information
Jena Murphy
jena.murphy@earnix.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom